Progress Study

IBSA Group and Inception Fertility want to make the embryo transfer process a little simpler for patients—and we need your help to make that progress.  

IBSA, a multinational pharmaceutical company, recognizes current methods of administering progesterone before and after a frozen embryo transfer (FET) can be painful, messy, and stressful for patients. The company has partnered with Inception Fertility and its family of brands, including the Prelude Network™, to complete a research study evaluating the effectiveness of administering progesterone by subcutaneous injection, an injection under the skin, rather than painful daily injections into a muscle or messy vaginal creams/gels or inserts.  

A hormone that plays an important role in early pregnancy, progesterone is considered the standard of care for support during the luteal phase of a woman’s menstrual cycle, when the lining of the uterus thickens to support a potential pregnancy. During a FET cycle, progesterone is usually administered for 4 days prior to the transfer. If the cycle results in a pregnancy, expectant mothers will continue to administer progesterone up to the 10-12th week of pregnancy. This study seeks to find an easier way to administer this vital hormone, helping to make the embryo transfer process more patient-friendly and less painful.  

Image of oura ring
Image of oura ring
IBSA Group and Inception Fertility want to make the embryo transfer process a little simpler for patients—and we need your help to make that progress.  

IBSA, a multinational pharmaceutical company, recognizes current methods of administering progesterone before and after a frozen embryo transfer (FET) can be painful, messy, and stressful for patients. The company has partnered with Inception Fertility and its family of brands, including the Prelude Network™, to complete a research study evaluating the effectiveness of administering progesterone by subcutaneous injection, an injection under the skin, rather than painful daily injections into a muscle or messy vaginal creams/gels or inserts.  

A hormone that plays an important role in early pregnancy, progesterone is considered the standard of care for support during the luteal phase of a woman’s menstrual cycle, when the lining of the uterus thickens to support a potential pregnancy. During a FET cycle, progesterone is usually administered for 4 days prior to the transfer. If the cycle results in a pregnancy, expectant mothers will continue to administer progesterone up to the 10-12th week of pregnancy. This study seeks to find an easier way to administer this vital hormone, helping to make the embryo transfer process more patient-friendly and less painful.  

Key Participant Requirements

The Progress Study is open to women ages 35-42 who have regular menstrual cycles (24-38 days) and are planning a single embryo transfer. Participants must:  

  • Have completed a normal uterine cavity evaluation within the past year (hysteroscopy, hysterosalpingogram, or SIS) 
  • Have a normal pap smear  
  • Must not have a medical history of severe endometriosis, recurrent pregnancy loss, diabetes mellitus, uncontrolled thyroid dysfunction, hepatic or renal impairment, autoimmune disease 

For a complete list of eligibility criteria, visit ClinicalTrials.gov: NCT04549116 

Key Participant Requirements

The Progress Study is open to women ages 35-42 who have regular menstrual cycles (24-38 days) and are planning a single embryo transfer. Participants must:  

  • Have completed a normal uterine cavity evaluation within the past year (hysteroscopy, hysterosalpingogram, or SIS) 
  • Have a normal pap smear  
  • Must not have a medical history of severe endometriosis, recurrent pregnancy loss, diabetes mellitus, uncontrolled thyroid dysfunction, hepatic or renal impairment, autoimmune disease 

For a complete list of eligibility criteria, visit ClinicalTrials.gov: NCT04549116 

During the study, participants who are eligible will:
An icon showing papers stacked on one another.

Attend scheduled clinic visits.

An icon of a hand
Have blood drawn to evaluate hormone levels.
An icon of rectangle, with a diagonal line over it.
Complete transvaginal ultrasounds designed to monitor changes to the ovaries, uterine lining, or pregnancy, if applicable.
An icon of rectangle, with a diagonal line over it.

Receive study medications to self-administer as instructed by the clinic staff.

During the study, participants who are eligible will:
Icon of a cell phone

Attend scheduled clinic visits.

Icon of a cell phone

Have blood drawn to evaluate hormone levels.

Icon of a cell phone
Complete transvaginal ultrasounds designed to monitor changes to the ovaries, uterine lining, or pregnancy, if applicable.
Icon of a cell phone

Receive study medications to self-administer as instructed by the clinic staff.

As part of the study, participants will receive

a credit toward their IVF/FET cycle cost, PGT-A testing via Igenomix, progesterone and Ovidrel, a medication that induces ovulation.

Sign up

Interested in participating in this study? Please complete this form to be considered.
An image of a doctor holding a clipboard
Inception Logo
Inception Fertility is the largest network of fertility centers in North America. Its family of brands is committed to helping aspiring parents build modern families while pursuing their fertility journeys on their own terms. Built by patients for patients, Inception seeks to set the highest bar for patient experience and outcomes through advanced reproductive science and technology.

©2023 Inception Fertility, Inc. All rights reserved.